Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

NCT: NCT04452149 · COMPLETED

NCT IDNCT04452149
StatusCOMPLETED
Start Date2020-09-03
Completion2025-06-02
SponsorMedtronic Cardiac Rhythm and Heart Failure (INDUSTRY)
First posted
Last updated

Brief Summary

The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study. The purpose of the study is to demonstrate the safety and efficacy of a patient management pathway that utilizes an integrated device diagnostic-based risk stratification algorithm to guide patient care in subjects with NYHA class II and III heart failure, and to demonstrate the safety of the Reveal LINQ™ system and procedure in the study population.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑